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Introduction
The forms of depression that fall below DSM and ICD threshold criteria can also be distressing and disabling if persistent (1) . Subclinical depressive symptoms and mild major depression are mostly managed in primary care (PC) (2) , but, in spite of the evidence currently available, there is no international consensus on the most appropriate therapeutic approach to them. PC is a complex system dealing with a broad range of physical, psychological and social problems. This lack of agreement among various countries may be associated to differences concerning professional, organizational context and political economic circumstances in PC systems, which affect the design and implementation of complex interventions.
In European countries, the first recommended treatment is usually a watchful waiting (WW) approach, also known as active monitoring or supportive care (1, 3, 4) . It involves a less insidious approach, with no formal intervention, consisting of discussing current problem(s) and any concerns that the person may have about them. In addition, GPs have the opportunity to provide information about the nature and course of depression, arranging for further assessment and considering low-intensity psychosocial and psychological interventions for patients who would benefit from them. In the UK, for instance, National Institute for Health and Care Excellence (NICE) guidelines propose a stepped care model for the management of depression, where WW is the first treatment step for patients with subclinical depressive symptoms and mild depression. These patients are monitored systematically and recommended a treatment of higher intensity when there is no adequate response (1) .
In the USA, in contrast, American Psychological Association (APA) guidelines recommend that acute phase treatment should include antidepressants (ADs) for all patients with major depressive disorder, including those with mild to moderate symptoms (5) .
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines aim for a more conservative approach, describing levels of evidence without giving specific recommendations in relation to concurrent combined treatment (pharmacotherapy plus psychotherapy), sequential combined treatment (start pharmacotherapy, add psychotherapy later) and crossover treatment (acute pharmacotherapy followed by switch to psychotherapy when well for maintenance) (6) .
The aim of the present study was to systematically review the clinical evidence supporting either WW or ADs for the treatment of subclinical depressive symptoms and mild major depression in a PC setting.
Methods
PRISMA guidelines for reporting systematic reviews were followed. The review protocol was entered into the PROSPERO International prospective register of systematic reviews (42016036345).
Literature search
A systematic review of the literature was performed for randomized and non-randomized controlled studies evaluating the clinical effectiveness of a non-pharmacological approach compared with the use of ADs for the treatment of subclinical depressive symptoms and mild major depression in PC. Four electronic databases were searched from inception to November 2016: PubMed, Web of Knowledge, PsycINFO and EMBASE. The search strategy used included terms related to (i) the presence of depression or depressive symptoms, (ii) non-pharmacological interventions for the management of depression (WW, supportive care, active monitoring; as well as a series of brief psychological and psychosocial interventions), (iii) PC and (iv) study design. The detailed electronic search strategy is displayed in a Supplementary Material. For the hand search, the reference list of all included citations was reviewed to recover additional articles not identified in the electronic search. Researchers with expertise in the topic of interest suggested relevant studies.
Inclusion criteria and study selection
The researchers screened, in duplicate, the articles identified in the search by first reviewing the title and abstract of the paper and, afterwards, by reading the full-text paper. Disagreements were resolved by discussion with a third author.
Study design
We selected all prospective controlled studies (randomized and non-randomized). Cost-effectiveness studies or other econometric analyses were excluded if clinical effectiveness results had previously been published. We included studies in English, Spanish, French and German.
Population
The studies had to include an adult population (≥18 years old) with new symptoms of subclinical depression or mild-moderate depression diagnosed with clinical interviews or diagnostic scales by the GP in a PC setting. PC is the first point of contact for people in need of health care, and may be provided by GPs, among other professionals. It is generally regarded as the first point of contact with the health care system and as a gateway to more specialized care. The aim is to provide an easily accessible route to care, whatever the patient's problem. Professionals working in PC deal with a broad range of physical, psychological and social problems, providing treatment for common illnesses, long-term illnesses and the prevention of future ill-health. In order to identify all papers fulfilling these criteria, we used terms related to primary health care, general practice, family practice and family medicine in our search strategy. In the present review, it was not necessary that the patient fulfilled all diagnostic criteria for a major depressive episode, as many of the patients consulting a GP may present with a series of emotional and depressive symptoms without attaining the diagnosis of major depression (7) . Diagnostic systems require at least one (DSM-IV) or two (ICD-10) key symptoms (low mood, loss of interest and pleasure, or loss of energy) to be present for the diagnosis of a major depressive disorder, plus five (DSM-IV) or four (ICD-10) accompanying depressive symptoms. Subclinical depressive symptoms consist of at least one key symptom of depression but without enough other symptoms and/or functional impairment to meet the criteria for full diagnosis (1) . As many of the people with depression may experience symptoms of more than one type of anxiety disorder (for example post-traumatic stress disorder, social phobias, panic disorder), comorbidities with anxiety symptoms were allowed. Conversely, the presence of psychotic symptoms was a reason for exclusion because it often indicates severe forms of the accompanying affective disorder, which is not the objective of our study.
Interventions
Patients in one of the groups (intervention group) must receive a WW approach. The definition of WW was based on existing clinical guidelines for the management of depression in PC (1, 3, 4, 8) . This treatment approach consists of taking no immediate action with respect to depressive symptoms and of following its progress intently through a series of follow-up consultations (9) . Although GPs are not asked to provide any specific intervention during this period, a variety of low-intensity psychosocial and psychological interventions is recommended (problem-solving techniques, counselling, brief or computerized cognitive-behavioural therapy or medical education). In another group (comparator group), patients had to start their treatment with AD and were also allowed to receive the same accompanying low-intensity interventions. Patients could also receive treatment with anxiolytics in both the intervention and control groups. Studies were excluded if structured psychotherapy or any specialized intervention by mental health professionals was developed in either of the groups.
Outcomes
We only included articles that reported clinical outcomes, including severity of depressive symptoms or other clinical variables such as anxiety, functionality or quality of life.
Quality assessment
The use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews because of the absence of empirical evidence and the lack of evaluation of other important potential biases (10) . The Cochrane Collaboration's recommended tool for assessing risk of bias is a domain-based evaluation, in which critical assessments are made separately for different domains (11) . Based on these recommendations and other related studies (12,13), we generated a series of quality criteria for the selected articles. We included questions related to the methodological approach and to the correct presentation and discussion of results. The quality questions considered and answered for each study are presented in Table 1 .
Data abstraction
Three reviewers used an abstraction form to extract, in duplicate, information on the characteristics, methods and outcomes of the retrieved studies. The abstraction form included information on the study design: setting, characteristics of the study population, total sample size, size of the control and intervention groups and date of the study. Outcome measures and variability were extracted for the sample of patients in the WW group and AD group. The scarcity of studies and the considerable clinical and methodological heterogeneity discouraged us from performing a meta-analysis. Thus, a qualitative synthesis was conducted.
Results
Literature search and study selection Figure 1 shows the flow diagram of studies identified in the search and screened for inclusion. The search of electronic databases identified 1546 studies. After reviewing the title and abstract of the articles, 57 articles were included for a review of the full-text paper. After the revision of the full-text articles, 54 were excluded for reasons shown in Figure 1 . The majority of articles (20) were finally excluded because there was no control group with ADs [most of the studies included the use of medication in patients receiving treatment as usual (TAU), comparing differences in efficacy between two An intention-to-treat analysis includes all randomized patients in the groups to which they were randomly assigned, regardless of the treatment they actually received and regardless of subsequent withdrawal from treatment or deviation from the protocol.
non-pharmacological interventions associated with TAU, but without differences in the prescription of ADs between the two study groups]. Seventeen studies were not included because there was an intervention by mental health specialists at some point of the study (for instance, psychologists or psychiatrists involved in the performance of cognitive-behavioural interventions). Other reasons for exclusion were the study design, the absence of a group of patients receiving a pure WW intervention, patients without a new episode of depression (for example patients with the diagnosis of dysthymia who were already receiving treatment with ADs), studies that were not carried by GPs in a PC setting and articles based on econometric analysis exclusively. Three papers were finally included in the synthesis. Table 1 shows the quality of the three studies included in the review. All the studies specified eligibility criteria, intervention and control patients recruited over the same time frame and point of the disease, randomized and concealed allocation, conducted sample size calculation and presented no selective reporting. Double blinding was not possible due to the nature of the intervention, thus none of them was considered of high quality.
Study quality
Baseline similarity is 'unclear' in Mynors-Wallis et al. (14) study because differences are observed in demographic features and adjustment is not performed. However, there is insufficient information to permit judgment on how these differences might influence the results. Differences related to the blinding of the outcome assessment are found between the three studies. Blinding of interviewers was only fully performed in the study by Mynors-Wallis et al. (14) . Differences between them are also observed in relation to incomplete outcome data. Mynors-Wallis et al. (14) present 'high risk' because there is an imbalance in numbers and reasons for missing data across intervention groups that might have induced bias. Kendrick et al. (15) was considered as 'unclear risk' because differences in withdrawals are seen but the reasons for missing data are not provided, hampering full judgement. Hermens et al. (16) , in contrast, shows balanced missing outcome data with similar reasons across treatment arms. Considering the absence of an intention-to-treat analysis in Kendrick et al. (15) study, the attrition bias due to the amount and handling of incomplete outcome data in Mynors-Wallis et al. (14) study, and the lack of point estimates and measures of variability in both studies, Kendrick et al. (15) and Mynors-Wallis et al. (14) articles were considered of low-moderate quality. Hermens et al. (16) study was considered of moderate-high quality because risk was only associated with the blinding of the outcome assessment and the absence of a double blinding, which is not possible on account of the nature of the intervention. Table 2 shows the characteristics of the studies included. Two of the studies were conducted in the UK (14, 15) and the other in the Netherlands (16) . All the selected articles were carried out after 1994. All of the studies were pragmatic randomized controlled trials conducted in PC. All of the studies had at least three assessments with follow-up periods that ranged from 16 to 52 weeks. There was a higher proportion of women in all trials. Mean age ranged from 34.5 to 40 years and total sample size ranged from 151 to 220 patients.
Study characteristics
The three studies included patients diagnosed as depressed, following diagnostic criteria and considering scores obtained from depression rating scales [The Hamilton Depression Rating Scale (HDRS) and the Montgomery-Åsberg Depression Rating Scale Clinically relevant difference as defined by the authors (clinically relevant differences ≥ 5 points in the MADRS). Table 2 . Although severity of symptoms was higher in one of the studies (14) , mean values and 95% confidence intervals in all three studies corresponded to scores of mild or moderate depression.
Results from the three selected articles Kendrick et al. (15) conducted a randomized controlled trial to determine the effectiveness and cost-effectiveness of selective serotonin reuptake inhibitor treatment plus supportive care, versus supportive care alone, for mild to moderate depression in patients with somatic symptoms in PC. Participants were diagnosed with new episodes of depression and potentially in need of treatment. Results from the study are summarized in Table 2 . Significant mean differences in favour of ADs in HDRS score adjusted for baseline were found at 12 and 26 weeks when analysed separately, but were relatively small. At 26 weeks, significance was lost after adjustment for missingness predictors. When a longitudinal analysis was conducted for improvements in the HDRS score, there was no evidence for a time per treatment interaction (P = 0.574) (17) . No differences between groups were observed in health-related quality of life. Mynors-Wallis et al. (14) performed a randomized controlled trial evaluating whether problem-solving treatment provided by a nurse in combination with AD medication was more effective than either treatment alone or problem-solving treatment provided by a GP in the management of major depression in PC. Table 2 outlines the study. There is a clear improvement in all groups over 12 weeks. However, the combination of problem-solving treatment and AD was no more effective than either treatment alone in any of the outcome measures assessed (HRDS, BDI, among others). There was no difference in outcome irrespective of who delivered the problemsolving treatment or the presence of pharmacological treatment.
Hermens et al. (16) conducted a pragmatic patient-randomized equivalence trial to compare the effectiveness of TAU, with or without AD, in minor and mild major depression. In this study, the TAU condition consisted of patients receiving education, information about depression and its prognosis, and advice on how to deal with depression in pre-scheduled 10-to 20-minute consultations with the GP. They performed an equivalence study to compare both treatment arms. Equivalence of TAU plus AD and TAU alone was demonstrated in the ITT analyses (at all follow-up points) as well as in the per protocol analysis after 6 weeks, but not at 13-, 26-and 52-week follow-up (Table 2 ). At 13, 26 and 52 weeks, statistically significant differences in clinical symptoms were observed in favour of ADs, although according to the authors definition, differences were only clinically relevant at 52 weeks in the per protocol analysis. No statistically significant differences between groups were observed in health-related quality of life.
The three studies are pragmatic randomized controlled trials where patients were recruited in PC clinics by GPs. All of the studies evaluated patients with baseline values indicating low to moderate intensity of depressive symptoms. Patients were evaluated at least twice after baseline assessment in order to monitor the improvement of depressive symptoms after two different treatment approaches, WW or ADs. A series of clinical scales were assessed showing a global improvement in depressive symptoms in all groups but with no statistically significant differences in effectiveness between the two treatment arms in any of the three studies. Size effect was not significant in any of the articles, although there was a tendency to clinically improve with ADs when less conservative strategies of analysis were conducted.
Discussion

Main findings
This review highlighted the fact that only three published studies have assessed the clinical effectiveness of WW in comparison to ADs when mild depression is treated in PC. None of them demonstrates a clear superiority of one treatment over the other. Kendrick et al. showed no evidence for a time per treatment interaction in the longitudinal analysis between the two groups, suggesting a small advantage for ADs only in the analysis that was conducted using a non-longitudinal analytical strategy. Mynors-Wallis et al. demonstrated that the combination of problem-solving treatment and AD medication was no more effective than either treatment alone. Finally, Hermens et al. found small statistical differences in effectiveness in favour of AD use only in the per protocol analysis, although these differences were not clinically relevant.
Factors influencing the scarcity of clinical evidence
Mild to moderate depression is mainly treated in PC. There is a large body of evidence on the effectiveness of several brief psychological and psychosocial interventions for the management of depression in this setting. We identified several studies evaluating WW (18) (19) (20) . However, few of them fulfilled our inclusion criteria. There are two main reasons for this. The first is that most studies compared WW with TAU (21) and the results were very difficult to interpret as the nature of the TAU condition varied across studies (22) . In some articles, TAU did not explicitly involve detection and treatment of depressive symptoms (23) . Conversely, in other studies, it was described as GPs suggesting external referral to specialized mental health care (24) . Second, many of the studies included specialized care at some point in the treatment process; for instance, psychiatrists conducting medication visits or psychologists engaging in the supervision of the intervention (18, 25) . In this regard, differences in the mental health system set up may prevent generalization of results to other contexts. In the last 20 years, there has been a significant expansion of specific psychological treatments in PC practice in the UK, in particular PC counselling developed by experienced counsellors (1). Many of the studies found in our systematic review were excluded because of the participation of these professionals in the development of brief psychological and psychosocial interventions (26) . This scenario described in the UK is not the same in all European countries. In many countries, GPs have limited or no access to brief-psychotherapy services performed by experienced psychologists or trained counsellors. In a study by Dumesnil et al. (27) , it is highlighted that French GPs are mostly inclined to start pharmacological treatment for depression immediately regardless of its severity because of their dissatisfaction about access to mental health specialists. In the Netherlands, van Marwijk et al. (28) pointed out the increase in workload imposed on GPs related to the treatment of depression and the need for close collaboration between GPs, mental health workers and pharmacies. In Spain, many studies have been published that focus on the lack of resources and the insufficient coordination between PC and Mental Health Services (29) (30) (31) . Consequently, the reason for excluding these types of interventions was to improve generalization to the greatest number of settings.
There is a high heterogeneity in the inclusion criteria described across the different studies. The articles identified used different instruments and criteria to diagnose depression, what may have led to misclassification of depression severity across studies and introduced some heterogeneity to the review. However, all three studies used validated scales (HDRS and MADRS) to assess severity of symptoms and, according to baseline description of the samples, all of them included patients presenting with mild or moderate depressive symptoms.
Factors influencing the choice of treatment
The literature does not yet allow us to draw solid conclusions on the superiority of any of the approaches in the treatment of subclinical depressive symptoms and mild depression. Although clinical guidelines base their recommendations on many different sources (including public consultation, mental health specialists and academics, among others), there seems to be a lack of scientific evidence supporting one treatment or another.
One of the main reasons that could influence the recommendation not to administer ADs as a first-line treatment is the large number of studies supporting the unlikely clinically advantage of drugs over placebo (32) . The placebo effect can be high and it can sometimes reach the same level of effectiveness (33, 34) . Improvements may be triggered by expectations and other placebo mechanisms rather than through specific drug effects (35) . The alternative, WW, does not only mean not administering the active substance to the patients but involves the patients in the decision to not immediately treat the condition with ADs and reassess it intermittently in followup consultations (9) , and that should not be equated with placebo.
Another aspect that could support this choice would be the undetermined benefit-risk ratio for patients when treated with ADs. While no standard recommendations exist, clinical decisions will lead to unsuitable treatment allocations (33) . Subclinical depressive symptoms often improve spontaneously or respond well to non-specific measures such as support and monitoring (36) . The more severe the symptoms, the greater the benefit of a pharmacological treatment (37) . Adverse effects are not usually reported in studies where ADs are compared with non-pharmacological approaches. Side effects should be systematically registered and reported in both treatment arms so as not to underestimate them when making the choice of treatment for these patients.
Taking all this into consideration, current guidelines recommend a stepped care model, where WW would be the first treatment step of all. The stepped care model is presented as a kind of collaborative care model where patients should be treated differently according to the severity of the episode. Collaborative care models should consider a multi-professional approach to patient care, scheduled patient follow-ups and enhanced inter-professional communication, including team meetings, case conferences, individual consultation/ supervision, etc (38) . However, a recent review by Van der Broeck et al. (39) suggests that limited guidance is provided to GPs in setting up regional collaborative care programmes and that studies are inconclusive in revealing the actual factors that are responsible for improved effectiveness compared to TAU. The review paper by van Straten et al. (40) points out how unclear medication management fits into stepped care programmes, possibly due to the high complexity of both programme and setting. There is still high heterogeneity in the interventions offered and further research is needed to examine how best these interventions could be implemented and financially supported (41) . Heterogeneity also applies to the professional providing the intervention. Kuramoto-Crawford et al. (42) underline the importance of the factors associated with provider type and organizational context in relation to the helpfulness of depression treatment. Results should be interpreted with care as inter-intervention variability is higher in complex non-pharmacological interventions.
In conclusion, despite the endorsement of many clinical guidelines, stepped care interventions (including WW) are still extremely heterogeneous and there is currently only limited evidence to recommend this model as the leading one in the treatment of depression (40) .
Consequently, a high proportion of patients treated in PC still end up using pharmacological treatment and the prescription rate of ADs tends to increase year by year in patients with mild depression. In Spain, for instance, the use of ADs increased by 200% from the year 2000 to the year 2013 (43) . This fact may be a reflection of many concurrent problems affecting PC services, including budget cuts, medicalization of social issues in the context of an economic crisis, shortage of health professionals and the consequent inability to perform brief psychological therapies, among others. The increasing use of pharmacological treatment might be a reflection of all these aspects related to the lack of social resources, time, training and inter-professional communication, leading to poor quality of care of depressed patients in PC. The inclusion of mental health care professionals such as counsellors or behavioural health care providers should be implemented and studied in our context as a potential strategy to reduce this increase in the use of medication.
The studies included in this review do not demonstrate the superiority of WW over treatment with ADs. On the contrary, results tend to indicate the greater effect of pharmacological treatment. In these circumstances, patients might suffer a delay in the treatment process and, consequently, a delay in clinical improvement when the initiation of AD treatment is postponed. Some clinical manifestations could respond better to pharmacological treatment, thus categorization of patients that would benefit from first-line pharmacological treatment may lead to the improvement of clinical guidelines in PC. A more precise definition of guidelines may reduce the risk of treatment delay and loss to follow-up, so reducing the burden on patients and society (44) (45) (46) .
Limitations and strengths
Our results have to be considered with caution due to several limitations. A meta-analysis could not be conducted because only three studies fulfilled the inclusion criteria. All the selected articles described studies conducted in Europe, where all clinical guidelines seem to favour a similar and more conservative treatment approach such as WW. Generalization to other health care systems may be limited. The studies may also have some limitations concerning the blinding of the outcome assessment and the absence of double blinding, which is not possible in these types of interventions. Although patients in all three studies presented with mild or moderate depressive symptoms, broad inclusion criteria regarding the diagnosis of depression may be introducing heterogeneity to the results and needs to be taken into account when interpreting these outcomes. Anxiety disorders were not considered as an exclusion criterion and might have been influencing the response to different treatments. The lack of a formal definition of the subject of interest generates a huge variety of interventions that may be confusing and completely different across studies. WW is a very broad concept, and unless it is defined in a more standardized way, results may be difficult to interpret. To minimize this aspect, we created strict inclusion criteria based on definitions from clinical guidelines, excluding therapeutic approaches other than pure WW methodology compared with treatment with ADs. As previously mentioned, there are many studies comparing several brief psychological and psychosocial interventions with TAU. However, there are many differences related to the professional carrying out the intervention, the setting and the comparator group, and results are very diverse. Moreover, most articles do not allow us to compare the different interventions with treatment with ADs, as in most the cases patients are not restricted in their use of medications and do not differ between treatment groups. Sample size was small in some of the studies and therefore, they may not have had sufficient power to detect statistically significant differences.
The protocol of this review was registered. Grey literature was not searched, and we might have missed some results on the topic. However, standardized procedures were used for the literature search and data extraction, including double reading to ensure quality. The reference lists of included articles and reviews were searched to minimize the number of missed articles. We included articles in four languages.
Conclusions
This article summarizes the gaps in scientific evidence supporting international clinical guidelines in the treatment of subclinical and mild depressive symptoms and is, as far as we know, the first review to compare a WW approach with AD treatment in PC. Our findings have three main implications. First, superiority is not demonstrated in any of the treatment arms, but it seems that there is a slight tendency to clinically improve with AD medication. It would be of great interest to study the clinical manifestations and other socio-demographic features that could influence the choice of and response to the different treatments prescribed. Second, there is an urgent need for a clear and structured definition of the WW intervention in a hypothetical collaborative care or stepped care approach. Third, GPs have limited time and resources, and the risk of treatment withdrawal is high. The presence of counsellors and specialists is not guaranteed in many countries in a PC setting, and it might therefore be necessary to reinvent the collaborative care concept to make it more accessible and feasible. More reliable data are needed to make any evidence-based recommendation regarding first-line treatment in the management of depressive symptoms in PC.
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